Coronary angioplasty via radial access using 4 Fr introducer. Minimally invasive to the extreme.

Original title: Comparison of frequency of Radial Artery Oclusion Alter 4Fr Versus 6Fr Transradial Coronary intervention (from the Novel Angioplasty Using Coronary Accessor Trial). Reference: Satoshi Takesita, et al. Am J Cardiol 2014;113:1986-89)

Since Andreas Gruentzig performed the first angioplasty, technological development has improved devices and radial access becomes more common.  This procedure reduces complications, mainly bleeding. However, although is clinically not relevant, there is a chance of radial artery occlusion in between 3% and 10%. 

In this multicenter, randomized, prospective study, 160 patients who received angioplasty by radial access with Allen test (+), were included, 80 with 4 Fr introducer and 80 with 6 Fr. We excluded those who required secondary branch protection by kissing balloon, cutting balloon, rotational atherectomy or IVUS not compatible with 4 Fr. The Primary Endpoint was the occlusion of the radial artery a day after the procedure and secondary was the procedural success, MACE, vascular access complications, procedure time and contrast used. The characteristics of both groups were similar, the mean age was 68 years, most men and more than 70% of coronary lesions were single (A or B1). Three patients (4%) of group 6 Fr presented occlusion of the radial artery and none in the 4 Fr group (p = 0.08). There was no difference with respect to the secondary endpoint except for the shorter hemostasis and vascular complications related to access. 

Conclusion: 

The use of radial access with introducer and 4 Fr catheters can become a less invasive alternative in simple coronary angioplasty.

Editorial comment

The use of 4 Fr in coronary angioplasty marks an important advance in this technique, but can be used in non-complex procedures only, giving benefit especially to patients with thin gauge arteries and prone to spasm. Further technological development are needed in order to perform complex angioplasties using compatible devices with 4 Fr. 

Courtesy of Carlos Fava
Cardiólogo Intervencionista
Fundación Favaloro
Buenos Aires

Dr. Carlos Fava

More articles by this author

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...